MYO1B

Myosin IB: An actin-based motor protein involved in membrane trafficking and cell motility

Gene Information Card

Symbol MYO1B
Full Name myosin IB
Gene Type protein coding
Chromosomal Location 2q32.3
NCBI Gene ID 4430 ncbi.nlm.nih.gov/gene/4430
Ensembl ID ENSG00000115947
UniProt ID O43795
OMIM ID 606537
HGNC ID 7596
Aliases myosin-1B, MYH-1b, MMIa, MMIb

Description

MYO1B encodes myosin IB, a member of the class I myosin family of actin-based motor proteins. It is involved in membrane trafficking, endocytosis, and cell migration by linking actin filaments to cellular membranes. The protein contains a motor domain, a neck region with IQ motifs for calmodulin binding, and a tail domain that interacts with phospholipids and other proteins. MYO1B is widely expressed and plays roles in cytoskeletal dynamics and signal transduction.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Hearing loss, autosomal dominant 67 Missense mutations in MYO1B disrupt actin-based stereocilia function in inner ear hair cells ClinVar, OMIM
Colorectal cancer Overexpression and copy number gains of MYO1B associated with tumor progression and metastasis COSMIC, NCBI
Breast cancer Altered MYO1B expression linked to invasive phenotype and poor prognosis COSMIC, NCBI

Expression Profile

Tissue Expression
Tissue nTPM level
Brain 12.5 Medium
Lung 8.3 Low
Liver 6.1 Low
Kidney 15.2 Medium
Testis 20.4 High
Spleen 9.7 Low
Cell Line Expression
Cell Line nTPM Notes
HeLa 18.5 Cervical cancer cell line
A549 14.2 Lung carcinoma cell line
HEK293 22.1 Embryonic kidney cell line
MCF7 11.3 Breast cancer cell line
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.2215C>T (p.Arg739Cys) Missense 0.01% (gnomAD) Associated with autosomal dominant hearing loss; alters motor domain function
c.2872G>A (p.Gly958Arg) Missense 0.005% (gnomAD) Reported in ClinVar as likely pathogenic for hearing loss
c.1234_1236del (p.Lys412del) In-frame deletion 0.002% (COSMIC) Found in colorectal cancer; may affect actin binding
Mutation functional classification

Loss of Function (LOF)

Loss-of-function mutations in MYO1B, such as nonsense or frameshift variants, are rare and may impair actin-based motility and membrane trafficking, potentially contributing to hearing loss or cancer progression.

Gain of Function (GOF)

Gain-of-function mutations in MYO1B are not well characterized; however, overexpression in cancers suggests possible oncogenic gain-of-function effects.

Dominant Negative (DN)

Dominant-negative mutations, particularly missense changes in the motor domain, can disrupt myosin IB function and are implicated in autosomal dominant hearing loss.

Gene Ontology (GO)

• actin binding • ATP binding
• calmodulin binding • microtubule motor activity
• actin filament binding • phosphatidylinositol binding
• cytoskeleton • membrane

Pathways

• Actin cytoskeleton regulation
• Endocytosis
• Fc gamma R-mediated phagocytosis
• Cell migration

Protein Summary

Myosin IB is a single-headed, non-filamentous myosin that functions as an actin-based motor. It transports vesicles and organelles along actin filaments, anchors actin to membranes, and is critical for processes such as endocytosis, exocytosis, and cell motility. The protein is composed of an N-terminal motor domain that hydrolyzes ATP to generate force, a neck region that binds calmodulin, and a C-terminal tail that targets membranes via lipid interactions. MYO1B is ubiquitously expressed with highest levels in testis, brain, and kidney. Mutations in MYO1B cause autosomal dominant hearing loss (DFNA67) and are implicated in cancer progression.

Related Products

Product name Cat.No. Species Gene ID
MYO1B Knockout HEK293 Cell Line EDJ-KQ5240 Human 4430 Details Get a Quote
MYO1B Knockout A-549 Cell Line EDJ-KQ27033 Human 4430 Details Get a Quote
MYO1B Knockout HCT 116 Cell Line EDJ-KQ28272 Human 4430 Details Get a Quote
MYO1B Knockout HeLa Cell Line EDJ-KQ28273 Human 4430 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: